Antiepileptic drugs and visual function.

[1]  P. Smith,et al.  Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. , 2006, Investigative ophthalmology & visual science.

[2]  G. Cavalleri,et al.  Vigabatrin Retinopathy in an Irish Cohort: Lack of Correlation with Dose , 2006, Epilepsia.

[3]  F. Proudlock,et al.  Oral gabapentin treatment for symptomatic Heimann-Bielschowsky phenomenon. , 2005, American journal of ophthalmology.

[4]  I. Sorri,et al.  Color vision and contrast sensitivity in epilepsy patients treated with initial tiagabine monotherapy , 2005, Epilepsy Research.

[5]  I. Sorri,et al.  Visual function in epilepsy patients treated with initial valproate monotherapy , 2005, Seizure.

[6]  P. Derambure,et al.  Retinal Electrophysiological Results in Patients Receiving Lamotrigine Monotherapy , 2005, Epilepsia.

[7]  K. Bhattacharyya,et al.  Acute myopia induced by topiramate: report of a case and review of the literature. , 2005, Neurology India.

[8]  C. Westall,et al.  Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. , 2004, Ophthalmology.

[9]  F. Chiarelli,et al.  Color vision in epileptic adolescents treated with valproate and carbamazepine , 2004, Seizure.

[10]  M. Pirmohamed,et al.  Drugs and the retina. , 2004, Expert opinion on drug safety.

[11]  S. Hosking,et al.  The effect of antiepileptic drugs on visual performance , 2004, Seizure.

[12]  E. Zrenner,et al.  Visual field constriction and electrophysiological changes associated with vigabatrin , 2002, Documenta Ophthalmologica.

[13]  J. Craig,et al.  Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma. , 2004, American journal of ophthalmology.

[14]  Frederick W. Fraunfelder,et al.  Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. , 2004, Ophthalmology.

[15]  M. Clarke,et al.  The effect of long-term use of benzodiazepines on the eye and retina , 2004, Documenta Ophthalmologica.

[16]  S. Andréasson,et al.  Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication , 2004, Documenta Ophthalmologica.

[17]  E. Bouzas,et al.  Clonazepam Associated Retinopathy , 2003, European Journal of Ophthalmology.

[18]  S. Sheth,et al.  A controlled study comparing visual function in patients treated with vigabatrin and tiagabine , 2003 .

[19]  S. Hosking,et al.  Patients Treated with Vigabatrin Exhibit Central Visual Function Loss , 2002, Epilepsia.

[20]  R. Nesher,et al.  [Bilateral acute angle closure glaucoma following topiramate treatment]. , 2002, Harefuah.

[21]  B. Gurler,et al.  Visual functions in epilepsy patients on valproate monotherapy , 2002, Journal of Clinical Neuroscience.

[22]  G. Harding,et al.  Field-specific visual-evoked potentials: Identifying field defects in vigabatrin-treated children , 2002, Neurology.

[23]  S. Wallace.  Newer antiepileptic drugs: advantages and disadvantages , 2001, Brain and Development.

[24]  D. Budenz,et al.  Presumed topiramate-induced bilateral acute angle-closure glaucoma. , 2001, American journal of ophthalmology.

[25]  Josemir W Sander,et al.  Long-term continuation of levetiracetam in patients with refractory epilepsy , 2001, Neurology.

[26]  D. Margineanu,et al.  Levetiracetam inhibits the high-voltage-activated Ca2+ current in pyramidal neurones of rat hippocampal slices , 2001, Neuroscience Letters.

[27]  E. Ben-Menachem,et al.  Vigabatrin Visual Toxicity: Evolution and Dose Dependence , 2001, Epilepsia.

[28]  M. Kalis,et al.  Oxcarbazepine, an antiepileptic agent. , 2001, Clinical therapeutics.

[29]  M. Boucart,et al.  Effects of lorazepam on vision and oculomotor balance. , 2001, Binocular vision & strabismus quarterly.

[30]  T. Vogt,et al.  VEP- und Elektroretinogrammveränderungen unter antikonvulsiver Therapie , 2000 .

[31]  C. Elger,et al.  Oxcarbazepine Placebo‐Controlled, Dose‐Ranging Trial in Refractory Partial Epilepsy , 2000, Epilepsia.

[32]  F. Chiarelli,et al.  Effects of antiepileptic drugs on evoked potentials in epileptic children. , 2000, Pediatric neurology.

[33]  B. Uthman,et al.  Safety of long-term treatment with tiagabine , 2000, Seizure.

[34]  N. Miller.  Using the electroretinogram to detect and monitor the retinal toxicity of anticonvulsants , 2000, Neurology.

[35]  F. Dreifuss,et al.  Levetiracetam for partial seizures , 2000, Neurology.

[36]  R. Kälviäinen,et al.  Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers , 2000, The British journal of ophthalmology.

[37]  R. Kälviäinen,et al.  Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy. , 2000, Ophthalmology.

[38]  T. Berendschot,et al.  Concentric Contraction of the Visual Field in Patients with Temporal Lobe Epilepsy and Its Association with the Use of Vigabatrin Medication , 2000, Epilepsia.

[39]  S. Nightingale,et al.  A controlled study of vigabatrin and visual abnormalities , 2000, The British journal of ophthalmology.

[40]  S. Sombati,et al.  Effects of Topiramate on Sustained Repetitive Firing and Spontaneous Recurrent Seizure Discharges in Cultured Hippocampal Neurons , 2000, Epilepsia.

[41]  J. O'Donnell,et al.  Lamotrigine Overdose in an Adult , 2000, Journal of toxicology. Clinical toxicology.

[42]  R. Shank,et al.  An Overview of the Preclinical Aspects of Topiramate: Pharmacology, Pharmacokinetics, and Mechanism of Action , 2000, Epilepsia.

[43]  G. Krauss,et al.  Visual dysfunction in patients receiving vigabatrin , 1999, Neurology.

[44]  G. Harding,et al.  Characteristics of a Unique Visual Field Defect Attributed to Vigabatrin , 1999, Epilepsia.

[45]  G. Harding,et al.  Visual field defects associated with vigabatrin therapy , 1999, Journal of neurology, neurosurgery, and psychiatry.

[46]  R. Hogan,et al.  Neuro-ophthalmological signs during rapid intravenous administration of phenytoin , 1999, Journal of Clinical Neuroscience.

[47]  A. Rabinowicz,et al.  Assessment of Colour Vision in Epileptic Patients Exposed to Single-Drug Therapy , 1999, European Neurology.

[48]  I. Leppik,et al.  Safety of tiagabine: summary of 53 trials , 1999, Epilepsy Research.

[49]  S. Noachtar,et al.  Gabapentin and carbamazepine affect eye movements and posture control differently: A placebo-controlled investigation of acute CNS side effects in healthy volunteers , 1998, Epilepsy Research.

[50]  Keiko Sato,et al.  Effects of Antiepileptie Drugs on Seizure Thresholds in the Rat Kindling Model of Temporal Lobe Epilepsy , 1998 .

[51]  A. Klistorner,et al.  Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin. , 1998, BMJ.

[52]  P. Schwartzkroin,et al.  Origins of the Epileptic State , 1997, Epilepsia.

[53]  W. Wisden,et al.  GABA(A)-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands. , 1997, Annals of medicine.

[54]  J. Dichgans,et al.  Color vision tests for early detection of antiepileptic drug toxicity , 1997, Neurology.

[55]  N. Sopranzi,et al.  [Felbamate: a long-term study in subjects with refractory epilepsy]. , 1997, Clinica Terapeutica.

[56]  B. Meldrum.  Update on the Mechanism of Action of Antiepileptic Drugs , 1996, Epilepsia.

[57]  W. Löscher,et al.  The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata , 1996, Brain Research.

[58]  G Bernardi,et al.  Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. , 1996, European journal of pharmacology.

[59]  D. Blum,et al.  Open label pilot study of oxcarbazepine for inpatients under evaluation for epilepsy surgery , 1996 .

[60]  D. Bergen.  Antiepileptic Drugs, 4th Ed , 1996, Neurology.

[61]  R. Mattson,et al.  The effect of gabapentin on brain gamma‐aminobutyric acid in patients with epilepsy , 1996, Annals of neurology.

[62]  Walter G. Bradley,et al.  Neurology in Clinical Practice: Principles of Diagnosis and Management , 1995 .

[63]  P. Calabresi,et al.  Action of GP 47779, the Active Metabolite of Oxcarbazepine, on the Corticostriatal System. II. Modulation of High‐Voltage‐Activated Calcium Currents , 1995, Epilepsia.

[64]  F. Matsuo,et al.  Lamotrigine: A six-month, placebo-controlled, safety and tolerance study , 1995 .

[65]  A. Dirican,et al.  Effect of valproate and carbamazepine on visual evoked potentials in epileptic children , 1995, Acta paediatrica Japonica : Overseas edition.

[66]  T. Hwang,et al.  Reversible downbeat nystagmus and ataxia in felbamate intoxication , 1995, Neurology.

[67]  R. Macdonald,et al.  Antiepileptic Drug Mechanisms of Action , 1993, Epilepsia.

[68]  M. Clarke,et al.  Maculopathy associated with diazepam , 1995, Eye.

[69]  M. Schmutz,et al.  Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. , 1994, European journal of pharmacology.

[70]  P. Schwartzkroin.  Cellular electrophysiology of human epilepsy , 1994, Epilepsy Research.

[71]  O. Kristensen,et al.  Therapeutic experiences with 947 epileptic out‐patients in oxcarbazepine treatment , 1993, Acta neurologica Scandinavica.

[72]  G. Zaccara,et al.  Effects of oxcarbazepine and carbamazepine on the central nervous system: computerised analysis of saccadic and smooth‐pursuit eye movements , 1992, Acta neurologica Scandinavica.

[73]  S. Preskorn,et al.  Tricyclic antidepressant-induced seizures and plasma drug concentration. , 1992, The Journal of clinical psychiatry.

[74]  P. Humphreys,et al.  Clobazam as an Add-on Drug in the Treatment of Refractory Epilepsy of Childhood , 1990, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[75]  R. Porter,et al.  Alcohol and Seizures: Basic Mechanisms and Clinical Concepts , 1990 .

[76]  I. Leppik,et al.  Carbamazepine-induced dyskinesia and ophthalmoplegia. , 1990, Cleveland Clinic journal of medicine.

[77]  J. Kurtzke,et al.  Primidone/phenobarbital-induced periodic alternating nystagmus. , 1989, Annals of Ophthalmology.

[78]  J. Schwarz,et al.  Phenytoin and Carbamazepine: Potential‐ and Frequency‐Dependent Block of Na Currents in Mammalian Myelinated Nerve Fibers , 1989, Epilepsia.

[79]  G. Chrousos,et al.  Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine. , 1987, American journal of ophthalmology.

[80]  R. Delorenzo,et al.  A Molecular Approach to the Development of Anticonvulsants , 1986, Annals of the New York Academy of Sciences.

[81]  R. Sandyk.  Total external ophthalmoplegia induced by phenytoin. A case report. , 1984, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[82]  W. Löscher,et al.  Valproate induced changes in GABA metabolism at the subcellular level. , 1981, Biochemical pharmacology.

[83]  E. Rodin,et al.  Carbamazepine-lnduced Oculogyric Crisis , 1979 .

[84]  F. V. Defeudis,et al.  GABA--biochemistry and CNS functions , 1979 .

[85]  P. Schechter,et al.  Attempts to correlate alterations in brain GABA metabolism by GABA-T inhibitors with their anticonvulsant effects. , 1979, Advances in experimental medicine and biology.

[86]  D. Johnston,et al.  The Influences of Phenytoin on the Fundamental Electrical Properties of Simple Neural Systems , 1977, Epilepsia.

[87]  B. Metcalf,et al.  4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. , 1977, European journal of biochemistry.

[88]  S. Hyams,et al.  Glaucoma due to diazepam. , 1977, American Journal of Psychiatry.